Bowman birk inhibitor concentrate and oral leukoplakia: A randomized phase IIb trial

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 410-418

  Armstrong, William B ^a   Taylor, Thomas H ^a,b   Kennedy, Ann R ^b   Melrose, Raymond J ^c   Messadi, Diana V ^d   Gu, Mai ^e   Le, Anh D ^b   Perloff, Marjorie ^f   Civantos, Francisco ^g   Goodwin, William Jarrard ^g   Wirth, Lori J ^h   Kerr, Alexander Ross ⁱ   Meyskens, Frank L ^a,j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UCLA SCHOOL OF DENTISTRY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^j and Public Health ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOWMAN BIRK INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 84877286018     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0004     Document Type: Article

References (29)

1. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83:541-6.
2. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-31. (Pubitemid 24127628)
3. Fournier DB, Erdman JW, Gordon GB. Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev 1998; 7:1055-65. (Pubitemid 28514109)
4. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6:4684-91. (Pubitemid 32110405)
5. Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998; 78:167-209. (Pubitemid 28255148)
6. Birk Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans. Int J Pept Protein Res 1985; 25: 113-31.
7. Kennedy AR. The status of human trials utilizing Bowman-Birk Inhibitor concentrate from soybeans. In: Soy in Health and Disease Prevention, edited by Michichiro Sugano, Taylor & Francis, Boca Raton, FL:2005;207-33.
8. Manzone H, Billings PC, Cummings WN, Feldman R, Clark LC, Odell CS, et al. Levels of proteolytic activities as intermediate marker end-points in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 1995; 4:521-7.
9. Billings PC, Carew JA, Keller-McGandy CE, Goldberg AL, Kennedy AR. A serine protease activity in C3H/10T1/2 cells that is inhibited by anticarcinogenic protease inhibitors. Proc Natl Acad Sci U S A 1987; 84:4801-5. (Pubitemid 17095839)
10. Brandt-Rauf PW. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res 1995; 333: 203-8. (Pubitemid 26024126)
11. Smit EF, Groen HJ, Splinter TA, Ebels T, Postmus PE. New prognostic factors in resectable non-small cell lung cancer. Thorax 1996; 51: 638-46. (Pubitemid 26226523)
12. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/ neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997; 71:173-9. (Pubitemid 27067265)
13. Wan XS, Meyskens FL Jr, Armstrong WB, Taylor TH, Kennedy AR. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomarkers Prev 1999; 8: 601-8. (Pubitemid 29337320)
14. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992; 10:1436-43. (Pubitemid 23059927)
15. Wu JT, Astill ME, Gagon SD, Bryson L. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. J Clin Lab Anal 1995; 9:151-65.
16. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 1994; 5:313-29.
17. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75(6 Suppl): 1418-25.
18. Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL Jr. Development of the Bowman-Birk inhibitor for oral cancer chemopre-vention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 2003; 113:1687-702. (Pubitemid 37210969)
19. SAS Online Doc® 9.1.3. 2007 September 22, 2012]; Available from: http://support.sas.com/onlinedoc/913/docMainpage.jsp.
20. Bradley JV. Distribution-free statistical tests. 1968, Englewood Cliffs, NJ: Prentice-Hall. xii, 388.
21. Dawson B, Trapp RG. Basic & clinical biostatistics. 4th ed; 2004, New York, NY: Lange Medical Books/McGraw-Hill, Medical Pub. Division. x, p. 438.
22. Mincer HH, Coleman SA, Hopkins KP. Observations on the clinical characteristics of oral lesions showing histologic epithelial dysplasia. Oral Surg Oral Med Oral Pathol 1972; 33:389-99.
23. Pindborg JJ, Daftary DK, Mehta FS. A follow-up study of sixty-one oral dysplastic precancerous lesions in Indian villagers. Oral Surg Oral Med Oral Pathol 1977; 43:383-90. (Pubitemid 8058336)
24. de la Parra C, Saldivar SO, Liu RH. Effect of processing on the phytochemical profiles and antioxidant activity of corn for production of masa, tortillas, and tortilla chips. J Agric Food Chem 2007; 55: 4177-83. (Pubitemid 46867431)
25. Mushine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double blind, placebo-controlled phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004; 10:1565-73. (Pubitemid 38435544)
26. Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspanc D, MacPhail L, et al. Randomized clincial trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23:921-7.
27. Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, De Paola LG, Siegel MA. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 1991; 72:425-9.
28. Kennedy AR, Szuhaj BF, Newberne PM, Billings PC. Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 1993; 19:281-302. (Pubitemid 23204845)
29. Fahey JW, Talalay P, Kensler TW. Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res 2012; 5:179-88.